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Small molecules that inhibit TNF signalling by
stabilising an asymmetric form of the trimer
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James O’Connell 1*, John Porter 1, Boris Kroeplien 1, Tim Norman1, Stephen Rapecki1, Rachel Davis1,
David McMillan 1, Tracy Arakaki2, Alex Burgin3,5, David Fox III4, Tom Ceska1, Fabien Lecomte1,
Alison Maloney1, Alex Vugler1, Bruce Carrington1, Benjamin P Cossins1, Tim Bourne1 & Alastair Lawson1

Tumour necrosis factor (TNF) is a cytokine belonging to a family of trimeric proteins; it has
been shown to be a key mediator in autoimmune diseases such as rheumatoid arthritis and
Crohn’s disease. While TNF is the target of several successful biologic drugs, attempts to
design small molecule therapies directed to this cytokine have not led to approved products.
Here we report the discovery of potent small molecule inhibitors of TNF that stabilise an
asymmetrical form of the soluble TNF trimer, compromising signalling and inhibiting the
functions of TNF in vitro and in vivo. This discovery paves the way for a class of small
molecule drugs capable of modulating TNF function by stabilising a naturally sampled,
receptor-incompetent conformation of TNF. Furthermore, this approach may prove to be a
more general mechanism for inhibiting protein–protein interactions.

1 UCB Pharma, Slough SL1 3WE, UK. 2 Covance Inc, Princeton, NJ 08540, USA. 3 Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA. 4 UCB
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Results
Fragments bind directly to TNF with slow binding kinetics. We
screened 2000 chemical fragments (MW < 300 Da) using surface
plasmon resonance (SPR) measurement on a Biacore 4000. The
fragments were passed over the Biacore chip surface coated with
immobilised TNF and screened at a concentration of 250 μM to
detect weak binders. This screen identiﬁed UCB-6786 (Fig. 1a)
and an analogue UCB-6876, which bound to TNF displaying a
concentration-dependent response curve and selectivity over the
TNFR1 extracellular domain and control proteins (Fig. 1b).
We next measured the binding kinetics of UCB-6876 for TNF
by SPR. Association rate constants (ka) for typical small molecules
are limited by the rate of diffusion and are commonly higher than
106 M−1s−1 18 but here the ka proved to be remarkably slow
(923 M−1s−1). Conversely, the dissociation rate constant of this
compound was also slow, particularly for a fragment (kd of
0.02 s1) resulting in a KD (kd/ka) of 22 μM. The slow kinetic
proﬁle is unusual for molecules of this size and the resulting curve
(Fig. 1c) did not have the square wave shape that is typical of
fragment binding.
Crystal structure and interactions of the TNF: compound
complex. Attempts were then made to obtain an X-ray co-crystal
structure by soaking apo-TNF crystals with compound and
conducting co-crystallisation trials, also in the presence of the
compound. In the soaking studies the presence of UCB-6876, but
2
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NF antagonist treatments have been one of the success
stories of recent years. Biologics such as inﬂiximab, etanercept, adalimumab, golimumab and certolizumab pegol
have proved efﬁcacious in the clinic and have a well-documented
mode of action and side-effect proﬁle1. Nonetheless, the use of
biologics remains restricted to a subset of the potential patient
population, as immunogenicity2, supply chain complexity3 and
health economics restrict their application. It is clear that many
more patients could beneﬁt from a small molecule drug with the
efﬁcacy of the anti-TNF biologics.
The compound SPD-304 targets TNF directly and has been
shown to inhibit activity by destabilising the TNF trimer,
resulting in a dimer that is no longer able to interact with
receptor4. Although this strategy has so far not led to molecules
capable of being developed, work is continuing in this area5–7.
The TNF trimer may also be induced to disassemble by aggregating small molecules8. These, however, behave as promiscuous
aggregators9 and the inhibition can be reversed with detergent, a
hallmark of promiscuous aggregators. Approaches have also been
described using natural products such as Japonicone A10, and
others have targeted the receptor rather than the TNF ligand11,12.
The status of small molecule inhibitors of TNF has been reviewed
in a number of articles13,14.
Small molecule modiﬁers of protein-protein interactions are
generally described as orthosteric or allosteric. The former compete directly with the two proteins for binding. There are a
number of examples described in the literature15,16. The potency
of TNF for TNF receptor 1 (TNFR1) is picomolar and despite the
interest in the ﬁeld generated by the success of the biologics, no
orthosteric small molecule inhibitors have been described. We
believe that disrupting the interaction allosterically17 through a
region of TNF that is not in direct contact with its receptor may
offer advantages that make this an attractive way to block its
mechanism of action. In this paper, we describe the discovery and
characterisation of a way in which antagonism of TNF signalling
is achieved in such a manner with low-molecular-weight compounds. This ﬁnding has the potential to broaden the availability
of the therapeutic beneﬁts of TNF inhibition.
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Fig. 1 Fragments bind to TNF with slow-binding kinetics. a SPR depicts the
binding of UCB-6786 to immobilised TNF. b The analogue, UCB-6876,
speciﬁcally binds to immobilised TNF (solid black circles) but not to control
proteins, capture antibody plus TNFR1 (solid black squares), capture
antibody (solid black triangle pointed down) or TNFR1 (solid black triangle
pointed up). c Kinetic analysis of UCB-6876 using the Biacore
T100 showing slow association and dissociation rates.

not a DMSO mock control, rapidly cracked and eventually dissolved the TNF crystals. In co-crystallisation trials, it prevented
the crystallisation of TNF under our standard conditions. After
screening for compound-dependent crystallisation conditions,
crystals diffracting to 2.5 Å were obtained for UCB-6876. The
structure was solved by molecular replacement using individual
monomers as a search model. The structure shows three TNF
monomers in the asymmetric unit (ASU) (Fig. 2a) and clear
electron density for one molecule of UCB-6876 bound at the
centre of the TNF trimer (Fig. 2b). The fold of the individual TNF
monomers was unchanged compared with apo-TNF (1TNF);
however, their spatial arrangement had changed, resulting in a
loss of the three-fold symmetry observed in all other published
structures of TNF. The compound was buried within the space
between the three TNF monomers and did not make any contact
with solvent. The key interactions appeared to be the hydrogen
bond from a benzimidazole N atom to Y151C (Y151 in chain C)
and π stacking of the benzimidazole with Y59C. The 2,5-dimethylbenzyl moiety of UCB-6876 ﬁlled a hydrophobic pocket,
assigned as Site 2, with compound TNF interactions composed of

NATURE COMMUNICATIONS | (2019)10:5795 | https://doi.org/10.1038/s41467-019-13616-1 | www.nature.com/naturecommunications

ARTICLE

NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-13616-1

a

Chain B

Site 3

Chain A

Chain C

b

c
B_L57
B_Y119

Site 2 A_Y59
C_Y59

Site 1

C_Y151

d

C

C
A
A

Fig. 2 Crystal structure of human TNF with UCB-6876. a Top and side views of TNF (green ribbons) with UCB-6876 bound (orange sticks). b Detail
showing the electron density of UCB-6876 and MPD bound within the TNF homotrimer. Monomers B (light green) and C (green) are shown surface
rendered. Contour level of the electron density is set at 1 sigma. MPD occupies a space next to UCB-6876. Subsequent molecules described in this paper
were modiﬁed to have chemical groups occupying the space where MPD was bound. c Detail of the compound-binding pocket within the TNF homotrimer,
with key residues involved in binding highlighted (sticks and labels). d Side view of apo-TNF (left image) and UCB-6876 bound TNF (right image) revealing
the distorted AC receptor-binding site (selected residues involved in TNFR1 binding are highlighted red).

Y59A, Y119B and L57B (Fig. 2c). It is also interesting to note that
a single molecule of methylpentanediol (MPD), a co-crystallant
required for crystal formation, was observed in an adjacent
pocket designated as Site 1 (PDB: 6OOY).
The asymmetry of the compound-bound TNF trimer results in
minor distortion at two of the receptor-binding sites and a more
signiﬁcant change at the AC binding site (i.e., the receptor-binding
site formed at the interface of the arbitrarily assigned A and C
monomers in the crystal lattice). There is a clear opening of the AC
site because of monomer A twisting and tilting down and away from
monomer C (Fig. 2d). By aligning compound-bound TNF with apoTNF (1TNF) through monomer C, the degree of movement of
selected residues involved in receptor binding on monomer A was
measured, revealing shifts of between 5.6 Å and 9.5 Å (Supplementary Table 1 summarises the movement of selected residues and

Supplementary Movie 1 uses the crystal structures of apo-TNF and
compound-bound TNF to show the overall change in TNF when
compound is bound.) Stereo images of portions of the electron
density maps can be found in Supplementary Fig. 1.
Stabilisation of TNF by small molecule binders. We were
interested in the mechanism of action of these inhibitors and
hypothesised that small molecules such as UCB-6876 are unlikely
to induce a large quaternary conformational change as seen here.
Also, the UCB compounds bind signiﬁcantly faster than
the timescale suggested for subunit exchange4. An enhanced
molecular dynamics simulation19 was used to investigate
the conformational transition between the symmetrical apo-TNF
and the asymmetrical, open conformation of the TNF trimer
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Fig. 3 TNF stabilisation by molecular dynamics and monomer exchange. a Meta-dynamics molecular dynamics simulation was used to produce this freeenergy surface. The simulation used a torsion describing the leaning angle of subunit A with respect to the other subunits and a distance describing how
open the AC cleft is. b Mass spectrometry analysis of a mixture of human TNF (orange circles) and mouse TNF (blue circles) showing peaks corresponding
to homotrimers and heterotrimers. c An equivalent analysis using human TNF pre-incubated with UCB-6876 (black triangle) showing that the compound
blocks the exchange of mouse and human monomers.

(Supplementary Fig. 2). These simulations were carried out
without the inclusion of our small molecule inhibitor in order to
understand the stability of the unbound asymmetric open conformation. The free-energy surface (FES) generated by this
dynamic model (Fig. 3a) shows two clear energy basins: the
symmetrical trimer (at 80 degrees leaning torsion and 11 Å cleft
distance) and a stable asymmetric trimer (marked with a red
cross). The shape of our FES suggests that the asymmetric open
state would be stable without a bound inhibitor, as there is a
signiﬁcant free-energy barrier to returning to the symmetric
closed conformation, which is calculated to be about 5 kcal mol−1
more stable. Hence, we expect that this new conformation of TNF
4

is formed by conformational selection as suggested by Double
Electron-Electron Resonance (DEER) analysis20 and stabilised by
UCB-6876. This model supports our hypothesis that the compounds can bind to and stabilise a naturally sampled transient
TNF trimer conformation. That UCB-6876 binds to a low
abundance form of TNF is consistent with the slow on-rate
observed by SPR, since the association rate constant is dependent
on binding site access and concentration. As indicated by the
crystal structure, once bound it is completely buried between the
TNF monomers, explaining the slow dissociation rate.
We conﬁrmed that the compounds stabilised the TNF trimer
by investigating their effect on the process of TNF monomer
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exchange. At low physiological concentrations, the trimer can
dissociate into monomers21, and these have been shown to
exchange with monomers from a different TNF molecule22,23.
To test this by mass spectrometry, we used mouse TNF, which
has a different molecular weight to human and has been shown to
exchange monomers by Biacore22. We ﬁrst showed that incubating a mixture of mouse and human TNF quickly produced
heterotrimers consisting of different ratios of mouse monomer
and human monomer (Fig. 3b). This suggests that the trimer can
re-form by exchanging monomers and dimers between mouse and
human TNF.
We then saturated human TNF with UCB-6876 and repeated
the experiment. This time only intact human and mouse TNF
homotrimers were observed, indicating that signiﬁcant exchange
of monomers between mouse and human TNF had not occurred
(Fig. 3c and Supplementary Table 2).

there was a dose-dependent shift from three receptors bound to
two (Supplementary Fig. 7a). At the highest compound
concentration (TNF fully occupied by UCB-5307) the major
species was the two-receptor bound form (Fig. 4a, brown trace).
Preloading hTNF with UCB-5307 blocked one receptor from
binding, so we next tested the ability of UCB-5307 to disrupt a
preformed hTNF/hTNFR1 complex. Complex formed using a
slight excess of receptor over TNF was challenged with the same
range of compound concentrations, and the results indicate that
UCB-5307 could penetrate the preformed complex, dislodging
one of the receptors (Supplementary Fig. 7b). At the highest
compound concentration, the degree of disruption was less
pronounced compared with that seen when preloading the TNF
with UCB-5307 (Fig. 4b, compare red and blue traces), and the
ratio of two receptor-bound to three receptor-bound species was
approximately equal (Fig. 4b, red trace).

Improving the afﬁnity of compounds for TNF for in vitro and
in vivo studies. To allow us to test for a functional effect in a cellbased assay we set out to improve the afﬁnity of these compounds. Comparison of the co-crystal structure to the symmetrical apo-TNF structure showed that the ligand binding pocket
was created by movement of Y119C together with movement of
the three TNF monomers relative to one another, creating space
for the compound. We extended UCB-6876 to occupy the MPD
binding pocket (termed Site 1 in Fig. 2b) to give the pyridyl
analogue UCB-5307 (Supplementary Fig. 3), which showed a
signiﬁcant improvement in potency (KD = 9 nM and kd 5.76E
−05 s−1; Supplementary Fig. 3) over UCB-6876. As expected, the
co-crystal structure of UCB-5307 (PDB: 6OOZ) showed that the
appended pyridyl group occupied the MPD pocket. The pyridyl
nitrogen formed an H-bond with Y119A, accounting for the
increase in potency (Supplementary Fig. 4). The overall degree of
TNF distortion had not changed, however, suggesting that the
increased potency is simply due to an increased afﬁnity, hence
stabilisation. Indeed, the level of TNF stabilisation measured by
thermal denaturation was signiﬁcantly increased in the presence
of UCB-5307 (Δ11.8 °C) compared with TNF in the presence of
DMSO alone (Supplementary Table 3).
We then turned our attention to Site 3, which extends towards
the solvent channel. We determined that this would be accessible
from the 5-position or 6-position of the benzimidazole. Addition
of a pyrazole group at this position produced UCB-9260 (PDB:
6OP0) (Supplementary Fig. 5), which bound TNF with a similar
KD of 13 nM but had a slower off-rate in the Biacore assay (kd =
4.39E−05 s−1; Supplementary Fig. 3), and resulted in further
stabilisation of the TNF trimer (Δ17.1 °C) (Supplementary
Table 3).

TNF small molecule compounds inhibit TNFR1 signalling and
downstream function in vitro. In order to assess the effect of the
compounds in the TNFR1 signalling pathway, we ﬁrst looked at
events proximal to TNFR1 by measuring signalling protein
recruitment to TNFR1, in particular RIP-1, which appears as a
ubiquitinylated ladder on gels24. In addition, we evaluated the
downstream signalling endpoint, phosphorylated NF-κB (pNFκB), which is distal to the TNF:TNFR1 signalling complex25.
After TNF stimulation alone, increased levels of RIP were
recruited to TNFR1, with a concomitant increase in phosphorylation of NF-κB (Fig. 5a, lane 2). However, when TNF was preincubated for 1 h with UCB-9260, recruitment of these proteins
to the TNFR signalling complex, and subsequent phosphorylation
of NF-κB, were markedly reduced to levels approaching those
seen when TNF was pre-incubated with the TNF biologic, etanercept (Fig. 5a). This demonstrated that these compounds
inhibited the ability of TNF-stimulated TNFR1 to recruit downstream proteins involved in signalling through NF-κB. We next
determined the cell potency and selectivity of compounds in a
high-throughput human cell-based reporter gene assay measuring
the response of SEAP-linked NF-κB to TNF (human or mouse)
stimulation in the HEK 293 cell-line. In the same system, we were
also able to test the selectivity to TNF by using an agonistic
monoclonal antibody to TNFR1 (0.3 μg/mL) to stimulate NF-κB
via the same pathway (Supplementary Fig. 8). UCB-9260 inhibited NF-κB with a geometric mean IC50 of 202 nM (95% CI = 53,
n = 8) after TNF stimulation (Fig. 5b Supplementary Fig. 9b), but
there was no inhibition of NF-κB stimulated by the TNFR1
agonist antibody. Since both TNF and the agonistic antibody
signal via the same pathway this indicates that the effect of UCB9260 is through TNF in this system.
We then tested if the compounds could inhibit both human
and mouse TNF-dependent functional activity by evaluating
UCB-9260 using a mouse cell L929 TNF-dependent cytotoxicity
assay, which had previously been used to characterise TNF
biologics in vitro26. UCB-9260 inhibited TNF-dependent cytotoxicity with a geometric mean IC50 of 116 nM, (95% CI = 15,
n = 203) and a geometric mean IC50 of 120 nM, (95% CI = 16,
n = 180) using human and mouse TNF, respectively (Fig. 5c and
Supplementary Fig. 9b). These data showed that the compound
inhibited the signalling and function of TNF and was suitable for
testing in mouse in vivo models.

Consequence of TNF distortion on receptor binding. We were
interested in the effect that distortion of the trimer would have on
receptor binding and the consequence for signalling activity in
cell and animal systems. We used analytical size exclusion
(AnSEC) to test if asymmetric TNF was compromised in its
ability to bind TNFR1.
To help interpret this, the migration proﬁle of human TNF
(hTNF) with one, two or three receptors bound was ﬁrst
characterised by titrating hTNFR1 with hTNF (Supplementary
Fig. 6). To measure the effect of compound, hTNF trimer was
incubated overnight with four concentrations of UCB-5307 prior
to incubation with a 3.2-fold excess of receptor. The compound
had little effect on the migration of hTNF alone (Fig. 4a, red and
blue traces), and in the absence of compound, a single peak was
observed corresponding to hTNF with three receptors bound
(Fig. 4a, green trace). As compound concentration was increased,

Mouse in vivo activity. Since UCB-9260 was to be used for
in vivo studies, we ﬁrst conﬁrmed that there were no selectivity
ﬂags using the CEREP ExpresSProﬁle panel. We then tested the
effect of this compound on other members of the TNF superfamily with trimeric structures similar at a superﬁcial level at least
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Fig. 4 Effect of compounds on TNF:TNFR1 stoichiometry. a Analytical size exclusion chromatography (AnSEC) of human (h) TNF alone (blue trace),
hTNF + UCB-5307 (red trace), hTNF + 3.2-fold excess hTNFR1 (green trace) and hTNF + 3.2-fold excess hTNFR1 + 690 µM UCB-5307 (brown trace).
Expected migration position of hTNF with two and three receptors bound are indicated by arrows. Standard trace shown in Supplementary Fig. 5. b AnSEC
comparing effect of 690 µM UCB-5307 on preformed hTNF/hTNFR1 complex (3.2-fold excess hTNFR1) (red trace) vs. hTNF preloaded with UCB-5307
followed by addition of 3.2-fold excess hTNFR1 (blue trace) as in experiment (a). Source data are provided as a Source Data ﬁle.

to TNF. We used thermal melting to test the ability of UCB-9260
to stabilise other members of the TNF superfamily in the presence
of DMSO compared with TNF (Supplementary Figs. 10, 11). No
other protein tested showed a signiﬁcant change in Tm, suggesting that the action of UCB-9260 is speciﬁc to TNF.
We were also interested in trying to understand why these
molecules were so selective for TNF over other family members.
This was particularly surprising because some of the family
members have similar residues to TNF at the binding site. We
tested one possibility: that compounds could not access the
binding site in the centre of the trimer of these proteins. We
noted by comparing crystal structures that TNF had a leucine at
position 57, whereas many of the other members of this family
had a larger phenylalanine or tyrosine. This is close to the binding
pocket, and in the symmetrical molecules these residues are close
to one another (one from each chain) thus forming a ‘gateway’ to
the pocket. Accordingly, we mutated Leu57 of TNF to
phenylalanine, mimicking other family members, to which our
compounds did not bind in a thermal melt assay. The mutated
TNF (L57F) was equally active as wild-type TNF in a HEK assay
6

(Supplementary Fig. 9c), but the compounds showed no activity
as demonstrated with UCB-9260 (Supplementary Fig. 9d).
Having conﬁrmed that UCB-9260 was selective for TNF over
other superfamily members, it was tested for activity in vivo
using a TNF-dependent mouse model. One such model measures
the ability of exogenous TNF injected into the mouse peritoneal
cavity to induce neutrophil recruitment27. Either human or
murine TNF can be tested because both signal through murine
TNFR128. We performed a dose-response experiment with UCB9260 to assess its ability to inhibit both TNF stimuli, compared
with a suitable anti-TNF biologic (CDP571)29 to inhibit human
TNF, and etanercept to inhibit murine TNF. Following oral
administration, UCB-9260 showed a dose-dependent inhibition
of neutrophil recruitment, measured as CD45+GR1+ cells by
ﬂow cytometry with signiﬁcant inhibition obtained at 30 mg/kg
of human TNF (Fig. 6a) and signiﬁcant inhibition of murine
TNF after a 10 mg/kg dose (Fig. 6b and Supplementary Table 4).
Additional supporting data using a zymosan-induced neutrophilia model can be found in Supplementary Fig. 12 and
Supplementary Table 5.
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Fig. 5 Inhibition of TNF signalling in cells. a Western blots measuring RIP1 ubiquitination following TNFR1 immunoprecipitation from Jurkat cells treated with
TNF ± UCB-9260 or etanercept. pNFkB expression was assessed, along with GAPDH for loading control. An isotype control antibody was included as an
immunoprecipitation control (lane 5). b TNF (10 pM) or anti-TNFR1 agonist antibody (0.3 mg/mL)-driven NFkB activity was measured following UCB-9260
treatment in Hek-293 cells using a reporter gene assay system. Representative concentration-response curves are shown. Percentage inhibitions for compound
dilutions were calculated between a DMSO control and maximum inhibition (by excess biologic anti-TNF, or NFkB inhibitor–TPCA-1). Untransformed data
shown in Supplementary Fig. 10c. c UCB-9260 inhibition of TNF (human or mouse) dependent cytotoxicity was measured in mouse L929 cells. Representative
concentration-response curves are shown. Percentage inhibition was calculated between unstimulated wells (maximum signal), and wells with TNF, DMSO and
actinomycin D (minimum signal). Untransformed data shown in Supplementary Fig. 10d. Source data are provided as a Source Data ﬁle.

The collagen antibody induced arthritis (CAIA) model uses a
combination of an anti-collagen antibody cocktail and lipopolysaccharide (LPS) to produce rheumatoid arthritis-like symptoms
in the mouse30. In this model, an in-house blocking murine
antibody (Ab501) showed profound inhibition of the clinical
score (Fig. 6c). UCB-9260, dosed orally at 150 mg/kg twice daily
(bid), 6 h after the LPS challenge (therapeutic dosing), also
showed a signiﬁcant reduction of the clinical score (Fig. 6c).
Statistically signiﬁcant inhibition in these models was associated
with unbound blood concentrations of compound that were
maintained above the in vitro human and mouse TNF IC50 values
(Supplementary Table 6).
Discussion
We have discovered orally active small molecules that inhibit
TNF activity both in vitro and in vivo. The compounds bind to a
pocket in the centre of the TNF trimer formed by the movement
of the TNF monomers, stabilising the distorted trimer, which
leads to reduced signalling through TNFR1. Analytical size
exclusion suggests that the asymmetric trimer only binds to two
receptors, consistent with the structural data showing signiﬁcant
distortion at one receptor binding interface. Rather than inducing
a conformational change, we believe that the compounds bind to
TNF through a process that is largely governed by conformational

selection as suggested by our molecular dynamic (MD) simulations (Fig. 3a) and DEER experimental data. We show here an
approach to inhibiting TNF through allosteric binding using
small, drug-like, orally available molecules that we believe stabilise a naturally occurring conformer of TNF.
Inhibiting protein-protein interactions (PPIs) with small
molecules has been described as reaching for the ‘high hanging
fruit’31. Indeed, the disruption of PPIs has been considered difﬁcult by medicinal chemists for many years and there are few
examples in the literature32. The surface between proteins is
typically large, ﬂat and featureless. Accordingly, many groups
choose to target these interactions using relatively large molecules
based on peptides or scaffolds that mimic peptides. Other
approaches, however, have been described, such as targeting ‘hot
spots’ in the binding site that appear to contribute most of the
binding energy, making smaller molecules a viable alternative33.
Notably, so-called fracturing of CD40L, a member of the TNF
superfamily, using a relatively large molecule retained the trimeric
assembly34. Indeed, there is some overlap between where this
compound binds on CD40L and the TNF binders described here.
Furthermore, stabilisation of protein complexes by binding
naturally occurring small molecules at the interface has also been
described35, and it is interesting to speculate that there could be
naturally occurring molecules that speciﬁcally modulate the
function of TNF. Most importantly, this work suggests a method
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Fig. 6 Oral treatment with UCB-9260 inhibits TNF-driven functional effects in vivo. a UCB-9260 (10–300 mg/kg po, PBS n = 4; vehicle n = 8; UCB9260 10, 30 and 300 mg/kg n = 6 and 100 mg/kg n = 8; CDP571 n = 5 mice) dose-dependently inhibits human and (b) mouse TNF-induced neutrophil
recruitment to the peritoneal compartment in mice (PBS n = 3; vehicle n = 8; UCB-9260 10 mg/kg n = 7, 30 mg/kg n = 6, 100 and 300 mg/kg n = 8;
CDP571 n = 5 mice). c UCB-9260 (150 mg/kg po bid) signiﬁcantly reduces arthritis clinical score in the CAIA model (vehicle n = 8; UCB-9260 n = 8 and
AB501 n = 6 mice). Mean data ± standard error is shown. *p < 0.05, **p < 0.01, ***p < 0.001 determined using one-way ANOVA with Dunnett’s multiple
comparison test. Exposure of UCB-9260 can be found in Supplementary Tables 4–6. Source data are provided as a Source Data ﬁle.

of discovering inhibitors using protein stabilisation of a nonactive conformation as an end point, which could be facilitated by
an antibody that holds the target protein in the desired inactive
conformation36. Here we demonstrate that fragment-based drug
discovery can be used to provide starting points for orally active
compounds that modulate protein-protein interactions.
Small molecules offer several advantages over biologics,
including cost, the convenience of oral delivery and shorter halflives, which beneﬁt patients requiring drug holidays. In addition,
they can be designed to diffuse across the blood-brain barrier,
making them suitable for targeting central nervous system disorders. The possibility of being able to target TNF-driven neuroinﬂammation, for example, is particularly interesting.
From our experience with TNF, it seems that orally available,
bona ﬁde small molecules, capable of stabilising favoured, naturally sampled conformations of target proteins, offer an attractive
and chemically tractable approach to tackling protein-protein
interactions.
Methods
Biacore binding assay. BIA (Biomolecular Interaction Analysis) uses SPR to
measure the binding of compounds to a protein immobilised on a chip surface. For
this purpose a Biacore A100/4000 (GE Healthcare) was used. A CM5 sensor was
8

immobilised via amine coupling on ﬂow cell 1 with human Fc antibody domain
(10k response units; kRU) and TNFR-Fc captured (2.5 kRU), ﬂow cell 2 TNF
(11 kRU), ﬂow cell 3 was left blank (for non-speciﬁc binding), ﬂow cell 4 TNFR-Fc
(10 kRU), and ﬂow cell 5 goat anti-human Fc 16 kRU). The sensor surface was then
equilibrated in HBS-P (10 mM HEPES pH 7.4, 0.15 M NaCl, 0.005% Surfactant
P20, BIAcore, GE Healthcare) with 5% DMSO for at least 5 h. Compounds were
diluted from 100 mM stocks into DMSO matched buffer and then ﬂowed over the
immobilised ﬂow cells at a concentration of 250 µM at the maximum ﬂow rate of
30 μL/min. Background subtraction binding curves were analysed using the Biacore
A100 BIA evaluation software version 1.1 following standard procedures.

Biacore kinetics of binding. Surface plasmon resonance using a Biacore T100/
T200 was used to measure the association rate constant (ka), the dissociation rate
constant (kd) and the afﬁnity (KD) of compounds. TNF (VCID 2043 Beryllium)
was immobilised to approximately 5 kRU as described above and equilibrated for at
least 5 h in HBS P + buffer with 5% DMSO. UCB-6876 was serially diluted from
187.5 µM, ﬂowing over the immobilised TNF at 50 µL/min for 3 min before
allowing full dissociation under ﬂow for at least 6 min. Kinetic constants were
obtained from multicycle data that had been double-referenced, the data ﬁtted and
then analysed using the Levenberg Marquardt algorithm in the BIA Evaluation
software (Biacore T100 BIA evaluation version 1.1). Compounds UCB-5307 and
UCB-9260 were titrated from 30 µM with three-fold serial dilutions to 0.37 μM and
ﬂowed over approximately 1.5 kRU of linked TNF with an n-terminal HKH tag
(Beryllium) in HBS P buffer with 5% DMSO at 100 μl/min. The compounds were
allowed to dissociate for 2 h under ﬂow. Kinetic constants from single-cycle data
were obtained (Biacore T100 BIA evaluation version 1.1) and compound characterisation details can be found in Supplementary Notes 1–4.
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Crystallography: plasmid construction. Human TNF (CID2043, UniProt P01375
residues 77–233 [full plasmid sequences available in the source data ﬁle]) was
codon-engineered in-silico using GeneComposer™ for E. coli expression, and
optimised to balance GC content, exclude cryptic Shine Dalgarno sequences, as
well as exclude BamHI and HindIII restriction sites. The ﬁnal gene insert was
ﬂanked with 5′ GGATCC (BamHI) and 3′ TGATAAGCTT (HindIII is underlined), such that two stop codons follow the C-terminal residue. The ﬁnal gene
insert was then synthesised by DNA 2.0 and delivered in a shuttle vector. Following
synthesis, the gene insert was digested with BamHI and HindIII and subcloned to
vector pEMB54, which is an ampicillin-resistant, arabinose-inducible vector with
pMB1 origin of replication and 6XHis-Smt3 under the PBAD promoter, followed
by a multiple-cloning site which includes BamHI followed by HindIII. After
BamHI/HindIII cloning into pEMB54, gene inserts are fused in-frame with the
6XHis-Smt3 sequence. Following digestion of both pEMB54 and CID2043 inserts
with BamHI/HindIII, both were gel-puriﬁed, the inserts ligated into the vector and
the ligation transformed to chemically competent TOP10 cells. One transformant
was mini-prepped and submitted for DNA sequencing of the Open Reading Frame.
CID7210 (see source data for plasmid sequence) was cloned in a manner similar to
CID2043, and consisted of a triple tandem fusion of the TNF ECD (‘TNF Trimer’),
wherein Uniprot P01375 77–233 was followed by 85–233, with an SG linker
between the TNF monomers. This gene (identical to CID3747) was optimised in
GeneComposer with identical BamHI/HindIII adaptors, synthesised by DNA 2.0
and subcloned into ﬁnal expression vector pEMB116, which is the same as
pEMB54 except the N-terminal tag is HKH instead of 6XHis-Smt3. CID8703 was
cloned via Quikchange mutagenesis (Agilent) using standard protocols, using
CID2043 as a template.
Crystallography: protein expression and puriﬁcation. Brieﬂy, the target-speciﬁc
vector was transformed into TOP10 E. coli cells. A starter culture containing
100 µg/mL (ﬁnal concentration) ampicillin (Teknova) was inoculated with a single
colony and grown for 16 h at 37 °C. This was then transferred to 8 L of Terriﬁc
Broth (Teknova) containing 100 µg/mL (ﬁnal concentration) ampicillin and grown
to OD600 = 0.6. Protein expression was induced by adding arabinose to a ﬁnal
concentration of 0.1% (VWR) and grown for 16 h at 25 °C. The cells were harvested by centrifugation (Beckman) at 6240×g for 15 min and the pellets were
collected and stored at −80 °C.
Cells were resuspended 1 g:4 mL in 25 mM Tris(hydroxymethyl)aminomethane
hydrochloride (Tris-HCl) pH 8.0 (Teknova), 200 mM NaCl (Teknova), 0.02% 3[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS) (JT
Baker), 50 mM L-arginine (Sigma), 500U of benzonase (Novagen), 100 mg
lysozyme (Sigma) and one complete EDTA-free protease inhibitor tablet (Roche).
The cells were lysed via sonication (Misonix) and clariﬁed via centrifugation at
142,000×g for 30 min at 4 °C (Beckman) and ﬁltered with a 0.2 µm bottle-top ﬁlter
(Nalgene). The supernatant was applied to two 5 mL Ni2+ charged HiTrap
Chelating HP (GE Healthcare) columns and the protein eluted with a 500 mM
imidazole gradient over 20 column volumes. The fractions of interest were pooled
and the His-Smt tag was removed via cleavage with Ubiquitin-like-speciﬁc protease
1 (Ulp-1) while dialysing against 2 L of 25 mM Tris pH 8.0 and 200 mM NaCl
overnight at 4 °C using 3.5 kDa MWCO snakeskin dialysis tubing. The afﬁnity tag
was removed by applying the digested pool over two 5 mL Ni2 + charged HiTrap
Chelating HP columns. The ﬂow-through contained the cleaved protein of interest.
The protein was concentrated for size exclusion chromatography via centrifugal
concentration (Vivaspin Polyethylsulfone, 10 kDa MWCO, Sartorius) to 13.5 mg/
mL for injection over a HiPrep 16/60 Sephacryl S-100 HR (GE Healthcare) in
10 mM HEPES (2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid), pH 7.5
and 150 mM NaCl. Fractions of interest were pooled and concentrated via
centrifugal concentration (Vivaspin Polyethylsulfone, 10 kDa MWCO, Sartorius) to
20 mg/mL, aliquoted and stored at −80 °C.
Crystallography: crystallisation. Puriﬁed human TNF was diluted to 4–7 mg/mL
in 10 mM HEPES pH 7.5, 150 mM NaCl buffer followed by overnight incubation at
4 °C with 0.5 mM compound (1–2 molar excess). The TNF-compound complex
was crystallised by sitting drop vapour diffusion by mixing 0.5 μL of complex with
0.5 μL of 13% MPD, 13% PEG 1000, 13% PEG3350, 0.1 M HEPES, pH 8.0. Crystals
were harvested for data collection ~2 weeks after initial set-up. Crystals were cryoprotected in ethylene glycol and/or vitriﬁed directly in liquid nitrogen for data
collection.
Crystallography: structure determination. The dataset for human TNF complexed with UCB-6876 and UCB-9260 were collected at the Stanford Synchrotron
Radiation Lightsource (SSRL) beam line 7–1 (ADSC Quantum-315R CCD X-ray
detector). The dataset for human TNF complexed with UCB-5307 was collected at
the Advanced Light Source (ALS) beam line 5.0.3 (ADSC Quantum-315R CCD Xray detector). Diffraction data were reduced and scaled with XDS/XSCALE37. The
structure was solved by molecular replacement using Phaser with input model of
1TNF. Iterative manual model building using Coot (Emsley and Cowtan, 2004)38
and Refmac (Murshudov et al., 1997)39 continued until R and Rfree converged.
Model quality was validated using Coot and MolProbity40. Structures were validated using Molprobity prior to deposition in the Protein Data Bank (PDB: 6OOY,
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PDB: 6OOZ, PDB: 6OP0)41,42. Statistics for each crystal structure are provided in
Supplementary Table 7.
Mass spectrometry monomer exchange. Mouse and human TNF protein were
made up to a concentration of 2 mg/mL (20 mM ammonium acetate, pH 7.4) and
desalted and buffer-exchanged using Zeba columns. The protein was then diluted
to 20 μM in ammonium acetate buffer. An aliquot of each was mixed 1:1 and
analysed at various time points. Human TNF was incubated (1:1, v/v) with compound (20 μΜ), 4% DMSO in 20 mM ammonium acetate) and mixed with mouse
TNF (1:1) and tested at various time points using an Advion Nanomate (for sample
introduction by nanospray) and ThermoFisher Exactive Plus EMR Mass Spectrometer. The following settings were utilised on the mass spectrometer: scan range
1000 to 8000 m/z; spray voltage 1.5 kV; capillary temperature 150 °C; S-lens RF
200; source DC offset 25 V, injection ﬂatapole 7 V; inter ﬂatapole 6 V; bent ﬂatapole DC 6 V; EMR mode on. Data were processed using ThermoFisher Protein
Deconvolution 3.0.
Molecular dynamics simulation. Missing backbone atoms were added using
FREAD43 database structure prediction software. An error in the amino acid
sequence of TNF structure 1TNF was detected within this process. In all three
monomers of PDB structure 1TNF residue 143 is a leucine; this is in contrast to
sequence data for TNF stored in Uniprot44 where this residue is an aspartate. For
this study residue 143 of 1TNF was mutated to an ASP. Maestro45 was then used to
add all other missing atoms and pick sensible protonation states for titratable
residues, ensuring that all homotrimers remained symmetric.
The ff99SB45 Amber force ﬁeld was employed for all protein parameters, set up
using the LEaP software from AmberTools 1.446. The TIP3P47 water model was
used in a solvating cube along with neutralising sodium chloride ions at an
approximate concentration of 0.15 M. NAMD 2.748 was used to carefully
equilibrate for temperature and pressure (300 K, 1 atm). ACEMD49 was then used
for a 1 ns structural equilibration and when patched with Plumed 1.350, for all
metadynamics simulations. ACEMD simulations used a 4 fs time step throughout.
All simulations used particle mesh Ewald51 for long-range electrostatics with
appropriate potential truncation and smoothing.
Initial metadynamics simulations used two CVs based on a quaternary torsion
and a distance (Supplementary Fig. 1c, d). Gaussians were added every 1 ps with an
initial height of 0.1 kcal mol−1. The bias-factor was set to 15. Gaussian widths were
set on a system basis using the last 200 ps of a 500 ps test run to estimate average
ﬂuctuation seen in 1 ps for each CV. A Gaussian width was chosen to be less than
half of the average 1 ps ﬂuctuation. Potential walls were employed to stop the
opening subunits from dissociating. In these cases the inversion conditions of
Crespo et al. were used to limit any error in the FES52. Wall and inversion
parameters were chosen in line with the Gaussian widths being used. Convergence
was pre-deﬁned as a Gaussian height <100 times smaller than the initial value,
convergence of any FE difference between open and closed states and free
movement across any energy barriers. Hence, once a signiﬁcant low energy region
is found away from the apo (symmetric homotrimer state) region, a return to the
apo region was deemed necessary.
PCA analyses of initial metadynamics simulations were carried out using the
GROMACS53 programmes g_colvar and g_anaeig. The most important
eigenvectors were chosen using the relative size of their eigenvalues.
Thermal denaturation assay of thermal stability. A ﬂuorescence probed thermal
denaturation assay was performed to assess the effect of the compounds on the
thermal stability of TNF (or other members of the TNF family) as a measure of
compound binding. The reaction mixture contained 5 µL of 30× SYPRO® Orange
dye (Invitrogen) and 5 µL of TNF (at 1 mg/mL), 37.5 μL PBS, pH 7.4 and 2.5 μL of
compound (at 2 mM in DMSO). The mixture (10 µL) was dispensed in quadruplicate into a 384 PCR optical well plate and was run on a 7900HT Fast RealTime PCR System (Agilent Technologies). The PCR System heating device was set
at 20 °C to 99 °C with a ramp rate of 1.1 °C min−1; ﬂuorescence changes in the
wells were monitored by a CCD device. The ﬂuorescence intensity increase was
plotted as a function of temperature and the Tm calculated as the midpoint of this
denaturation curve (determined as the point of inﬂection).
Analytical size exclusion chromatography. A stock of compound bound to
human (h) TNF was prepared by pre-incubating hTNF (300 μM, molecular weight
based on the homotrimer) overnight at 4 °C with UCB-5307 at a ﬁnal concentration range from 90 μM to 690 μM, maintaining a constant DMSO concentration of 1%. The compound-bound hTNF was incubated for 1 h at 22 °C with
hTNFR1 at a 3.2-fold molar excess over homotrimers (ﬁnal concentrations:
hTNFR1 240 μΜ, hTNF 75 µM). Identical samples were prepared with DMSO
only, giving a ﬁnal DMSO concentration of 0.25% for both sets of samples.
Alternatively, a fully assembled hTNF/hTNFR1 complex (3 receptors per homotrimer) was formed by incubating hTNF with a 3.2-fold molar excess of hTNFR1
for 1 h at 22 °C. The TNF/TNFR1 complex was then incubated overnight at 4 °C
with UCB-5307 at a ﬁnal concentration range from 90 µM to 690 µM. Samples
were subject to analytical size exclusion using HPLC. Injection volumes of 50 µL
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were separated on a TSK G3000SW L × I.D. 30 cm × 7.5 mm column (10 µm
particle size) pre-equilibrated in 10 mM HEPES, pH 7.5, 150 mM NaCl.
TNFR1 immunoprecipitation and signalling assay. TNF (25 ng/mL) was preincubated with UCB-9260 (10 µM) or anti-TNF (20 µg/mL, Etanercept, GlobalRx)
for 1 h at 37 °C, and then incubated for 5 min at 37 °C with 50 × 106 Jurkat cells.
Cells were then lysed for 1 h in cold lysis buffer (1% NP-40, 150 mM NaCl, 50 mM
Tris pH 8.0, 25 mM NaF, 1 mM vanadate, 1% phosphatase inhibitor and 0.2%
protease inhibitor cocktail), and cell supernatant harvested. TNFR1 immunoprecipitation was performed by incubating supernatant with 5 µg anti-TNFR1 antibody (R&D systems, #AB-225-PB) overnight while rotating at 4 °C, followed by the
addition of 20 µL protein G sepharose beads for 1 h rotating at 4 °C. An isotype
control sample was incubated with 5 µg goat IgG, instead of anti-TNFR1 antibody
to assess how much unspeciﬁc binding to the beads occurs during immunoprecipitation. Beads were subsequently washed 3× in lysis buffer, and then the supernatant removed and SDS-PAGE reducing sample buffer added to beads and
samples boiled for 10 min. Sample (15 µL) was then loaded on a 4–12% Bis-Tris gel
and run for 65 min at 200 V in MOPS buffer. Gels were then transferred to
nitrocellulose membrane using iBlot (Invitrogen) and blocked in 5% milk in TBS/
0.05% Tween (blocking buffer) for 1 h. RIP-1 ubiquitination (1:250 dilution, BD,
#610459) was then detected by Western blotting using anti-mouse-HRP (1:2000
dilution, Cell Signalling Technology, #7076). pNFκB (1:1000 dilution, Cell Signalling Technology, #3033) and GAPDH (1:4000 dilution, Cell Signalling Technology, #5174) were measured in the total cell lysates by Western blotting using
anti-rabbit HRP (1:2000 dilution, Cell Signalling Technology, #7074). Blots were
developed by detecting chemiluminescence using ImageQuant (GE Healthcare).
TNF reporter gene assay using a HEK Blue MediaTM readout. Stimulation of
HEK-293 cells by TNF leads to activation of the NF-κB pathway. The HEK-BlueTM
CD40L SEAP (secreted embryonic alkaline phosphatase) reporter cell line used to
determine TNF activity (InvivoGen, #hkb-CD40, cells were described as mycoplasma free when purchased and were tested using Mycoalert [Lonza] after each
batch of assay vial preparation). Compounds were titrated in DMSO and preincubated with TNF at a concentration giving half maximal response (10 pM for
human or 20 pM for mouse) or the anti-human TNFR1 agonist antibody (R&D
Systems. #AF 225) for 1 h. Cells were added to the compound/stimulus mixture
and further incubated for 18 h. SEAP was measured using the colorimetric substrate HEK-Blue DetectTM or QUANTI-BlueTM from InvivoGen. Percentage
inhibitions for compound dilutions were calculated between a DMSO control and
maximum inhibition (by excess anti-TNF biologic, or NF-κB inhibitor–TPCA-1
[Tocris #2559, R&D Systems]). The IC50 was determined as the point of inﬂexion
between the ﬁtted minimum and maximum of the compound dose response curve,
calculated using 4PL ﬁtted curve. Mean IC50s are reported as a mean of at least two
experiments. Dose response curves for TNF and the anti-human TNFR1 agonist
antibody are shown in Supplementary Fig. 9.
TNF L929 cytotoxicity assay. TNF (human or mouse) kills L929 cells which have
been compromised by incubation with a sub-lethal concentration of actinomycin
D, and this effect is inhibited with TNF biologics18. Compounds were titrated in
DMSO, and then pre-incubated with human or mouse TNF for 1 h. L929 cells
(ECACC, #85011425) in media containing actinomycin D (2 µg/mL) were added to
the TNF inhibitor mixture and incubated for 18 h. L929 cytotoxicity was measured
by the addition of CellTitreGlo (Promega). Luminescence was measured after an
incubation of at least 20 min in the dark. Percentage inhibition was calculated
between unstimulated wells (maximum signal), and wells with TNF, DMSO and
actinomycin D (minimum signal). The IC50 was calculated as the point of inﬂexion
for a 4PL ﬁtted curve. Mean IC50s are reported as a mean of at least two experiments. Cells were described as mycoplasma-free when purchased and were tested
using Mycoalert (Lonza) after each batch of assay vial preparation.

Collagen antibody induced arthritis model. Adult male Balb/c mice (aged
6–8 weeks, vehicle n = 8; UCB-9260 n = 8 and AB501 n = 6 mice, from Charles
River UK) received 4 mg of anti-collagen type II antibody cocktail intraperitoneally,
which was followed 24 h later with 25 µg of lipopolysaccharide (LPS) intraperitoneally. Dosing with vehicle (30% cyclodextrin po bid) or UCB-9260 (150 mg/kg
po bid) was initiated 6 h post-LPS administration. Ab501 (in-house anti-mouse
TNF antibody, 100 m/kg) was administered intravenously 6 h post-LPS administration followed by three further doses administered subcutaneously at 48-h
intervals. Animals were scored for signs of arthritis and weighed daily. The following scoring system was used for signs of arthritis: 0-no arthritis, 1-wrist/ankle
affected, 2-wrist/ankle and pad affected and 3-wrist/ankle, pad, and digits affected.
Data shown as the mean ± standard error of arthritis clinical score for the treatment group. Statistical signiﬁcance (*p < 0.05, **p < 0.01) was determined using
one-way ANOVA with Dunnett’s multiple comparison test.
All in vivo studies were reviewed by an internal ethical review body and
conducted in accordance with the Animals (Scientiﬁc Procedures) Act 1986, EU
Directive 2010/63/EU. Animals were kept under a light/dark cycle of 12/12 h and
had access to food and water ad libitum.
Zymosan induced neutrophil recruitment in vivo. Adult male Balb/c mice (aged
6–8 weeks, PBS n = 5; vehicle n = 8; UCB-9260 10, 30, 100 and 300 mg/kg n = 8;
Ab501 n = 3 mice, from Charles River UK) were dosed intravenously with 30 mg/
kg of Ab501 (in-house anti-mouse TNF antibody) diluted in PBS 1 h prior to
zymosan challenge. Vehicle (30% cyclodextrin) or UCB-9260 at 10, 30, 100 and
300 mg/kg was dosed orally at the time of zymosan challenge. Zymosan (R&D
Systems) was administered by intraperitoneal injection at a concentration of 1 µg
per mouse in PBS (100 µL). One hour post oral administration of UCB-9260, mice
were bled via the tail to analyse exposure levels of the compound. Four hours after
the zymosan challenge, mice were sacriﬁced and the peritoneal cavity lavaged with
3 mL of FACS buffer. An aliquot (0.3 mL) of lavage ﬂuid was used to assess the
number of CD45+GR1+ cells by ﬂow cytometry. Brieﬂy, the cells were treated with
ACK lysis buffer, washed and suspended in FACS buffer prior to staining with
FITC anti-mouse CD45 and PE anti-mouse GR1 (BD Biosciences). Data are shown
as mean ± standard error of the number of CD45+GR-1+ cells. Statistical signiﬁcance (*p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001) was determined
using one-way ANOVA with Dunnett’s multiple comparison test.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.

Data availability
The data supporting this study are available from the corresponding author upon
resoanable request. The structural data have been deposited with the Protein Data Bank
under accession codes 6OOY for UCB-6876, 6OOZ for UCB-5307, and 6OP0 for UCB9260. NMR spectral data are available for UCB-5307 (Supplementary Figs. 13, 14) and
for UCB-9260 (Supplementary Figs. 16, 17). High resolution mass spectrometry (HRMS)
is also available for UCB-5307 (Supplementary Fig. 15) and UCB-9260 (Supplementary
Fig. 18). The source data underlying Figs. 4 and 6, Supplementary Figs. 6–9 and 12, and
Supplementary Tables 4–6 are provided in the source data ﬁles.
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